Group 1 - Blackstone has successfully raised $6.3 billion for its life sciences investment strategy, marking the largest private fund ever raised in this sector [1] - The BXLS platform has allocated nearly $2 billion to various life sciences companies over the past year, including a significant $700 million investment in MSD for the development of an antibody-drug conjugate [2] - The platform also invested $400 million in Teva Pharmaceutical's duvakitug program and partnered with Johnson & Johnson for future clinical trials of an AML drug [3] Group 2 - Blackstone Life Sciences has achieved 34 approvals for innovative medicines and devices, including notable therapies like Alnylam Pharmaceuticals' ATTR therapy and AbbVie & J&J's BTK inhibitor [4] - The recent funding round reflects Blackstone's strong commitment to the life sciences sector, which remains a core focus area for the firm [5] - The life sciences sector is currently facing challenges due to rising interest rates and economic uncertainty, but there are signs of recovery in pharma funding, with a 70.6% increase in venture capital investments in Q4 2025 compared to Q3 [6][7] Group 3 - There is a notable shift in investor activity towards cell and gene therapy, with increased interest in Series B-stage candidates as investors become more selective [8]

Group 1 - Barclays has cut the price target for Blackstone Inc. (BX) from $164 to $126 while maintaining an Equal Weight rating, citing early uncertainty regarding the impact of AI on portfolio companies and lowering earnings estimates for business development companies due to reduced flow assumptions [1] - Blackstone Life Sciences (BXLS) announced a funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor for acute myeloid leukemia (AML), which is noted as a challenging ailment with the lowest survival rates among leukemia types [2] - The co-funding agreement between Blackstone Inc. and Johnson & Johnson for the clinical trials of bleximenib marks a significant collaboration, indicating a strategic partnership in the healthcare sector [3] Group 2 - The investment landscape is shifting, with certain AI stocks being perceived as having greater upside potential and lower downside risk compared to Blackstone, suggesting a competitive environment for investment opportunities [4]

Group 1 - Blackstone Inc. is recognized as one of the best cheap blue chip stocks to buy, with analysts highlighting its potential [1] - Blackstone Life Sciences announced a funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor for acute myeloid leukemia (AML), which is noted for its challenging treatment and low survival rates [1] - Johnson & Johnson and funds managed by Blackstone Life Sciences will co-finance ongoing and future clinical trials of bleximenib, marking their first co-funding agreement [3] Group 2 - RBC Capital initiated coverage of Blackstone Inc. with an Outperform rating and a price target of $179, citing the company's first-mover advantage in launching a private wealth team and its potential to benefit from retail growth and an improving real estate cycle [4] - Blackstone Inc. provides investment and fund management services across several segments, including Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions [5]